Alterity Therapeutics Limited (ASX:ATH)
0.0070
-0.0010 (-12.50%)
Jan 30, 2026, 12:34 PM AEST
Alterity Therapeutics Revenue
In the fiscal year ending June 30, 2025, Alterity Therapeutics had annual revenue of 5.44M AUD with 35.32% growth. Alterity Therapeutics had revenue of 3.83M in the half year ending June 30, 2025, with 150.44% growth.
Revenue
5.44M
Revenue Growth
+35.32%
P/S Ratio
16.00
Revenue / Employee
604.32K
Employees
9
Market Cap
87.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.44M | 1.42M | 35.32% |
| Jun 30, 2024 | 4.02M | 102.95K | 2.63% |
| Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
| Jun 30, 2022 | 5.12M | 783.93K | 18.06% |
| Jun 30, 2021 | 4.34M | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 66.87M |
| Radiopharm Theranostics | 12.51M |
| Amplia Therapeutics | 5.01M |
| Imugene | 4.40M |
| Prescient Therapeutics | 4.36M |
| Arovella Therapeutics | 3.44M |
| Proteomics International Laboratories | 3.31M |
| Cynata Therapeutics | 1.89M |
Alterity Therapeutics News
- 8 days ago - Alterity Therapeutics (ATHE) Advances towards Phase 3 Trials with Promising MSA Treatment - GuruFocus
- 2 months ago - Alterity Therapeutics (ATHE) Pioneers Unique Approach to Neurodegeneration - GuruFocus
- 2 months ago - Alterity Therapeutics (ATHE) Focuses on Parkinson's Disease Research - GuruFocus
- 2 months ago - Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference - GlobeNewsWire
- 3 months ago - Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report - GlobeNewsWire
- 4 months ago - Alterity Therapeutics (ATHE) Unveils Promising Phase 2 Results for ATH434 in MSA - GuruFocus
- 4 months ago - Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 4 months ago - Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire